01 1Cipla
01 1DOLUTEGRAVIR SODIUM (FORM C)
01 1India
01 1Active
01 1Complete
GDUFA
DMF Review : Complete
Rev. Date : 2017-03-01
Pay. Date : 2016-11-07
DMF Number : 31107
Submission : 2017-02-11
Status : Active
Type : II
20
Cipla Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is DOLUTEGRAVIR SODIUM (FORM C), with a corresponding US DMF Number 31107.
Remarkably, this DMF maintains an Active status since its submission on February 11, 2017, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of March 01, 2017, and payment made on November 07, 2016, indicating their dedication to facilitating drug approvals, Categorized as Type II
